Clinical trial
An Open-label Phase I/II Clinical Study of MHB088C for Injection Combined With MHB039A for Injection in Patients With Advanced Malignant Solid Tumors
NCT07126665 is registered in ClinicalTrials.gov with Minghui Pharmaceutical (Hangzhou) Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Phase I/II Clinical Study of MHB088C for Injection Combined With MHB039A for Injection in Patients With Advanced Malignant Solid Tumors
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 18, 2025
- Completion date
- August 31, 2031
- Enrollment
- 116 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid tumor